中低位直肠癌的精准诊断与规范治疗
Precision diagnosis and standardized treatment of mid-low rectal cancer
杨鋆 1辛城霖 1张忠涛1
作者信息
- 1. 首都医科大学附属北京友谊医院普通外科中心 国家消化系统疾病临床医学研究中心消化健康全国重点实验室,北京 100050
- 折叠
摘要
结直肠癌是我国主要消化系统疾病,并以中低位直肠癌为主.经过数十年发展,我国结直肠外科取得长足进步,在临床诊断与治疗、科研探索和数据平台建设等方面,均取得一定建树,但仍需提高诊断的精准度与治疗的规范化.此外,以程序性死亡受体1为代表的免疫检查点治疗,在中低位直肠癌治疗中初显成效,需进一步探索免疫检查点抑制剂与传统放化疗之间的关系和作用,将之转化为精准的临床实践.笔者深入阐述我国中低位直肠癌的诊断与治疗现状,以期为直肠癌精准诊断与规范治疗提供参考.
Abstract
Colorectal cancer is a major digestive disease in China,with mid-low rectal cancer as the predominant cause.Over the years,Chinese colorectal surgery has made considerable strides,attaining certain successes in clinical diagnosis and treatment,scientific research,and data platform construction.Nevertheless,there is still room for improvement in terms of the accuracy of diagnosis and standardization of treatment.Furthermore,immune checkpoint therapy represented by programmed death-1 have demonstrated initial efficacy in the treatment of mid-low rectal cancer.Further research is required to better understand the relationship and role between immune checkpoint inhibitors and traditional radiotherapy and chemotherapy,and to apply them to precise clinical practice.The authors elaborate on current status of diagnosis and treatment for mid-low rectal cancer in China,in order to provide references for its precission diagnosis and standardized treatment.
关键词
直肠肿瘤/中国结直肠癌手术病例登记数据库/中国经肛全直肠系膜切除病例登记协作研究/免疫治疗/新辅助治疗/磁共振成像Key words
Rectal neoplasms/Chinese colorectal cancer surgery database/Chinese trans-anal total mesorectal excision registry collaborative/Immunotherapy/Neo-adjuvant therapy/Magnetic resonance imaging引用本文复制引用
基金项目
国家科技支撑计划(2015BAI13B09)
国家重点研发计划(2017YFC0110904)
北京市临床重点专科基金卓越项目(2018-118)
北京市自然科学基金海淀原始创新联合基金(L222149)
北京市属医院科研培育项目(PX2022002)
首都医科大学结直肠肿瘤临床诊疗与研究中心基金(1192070313)
出版年
2024
NETL
NSTL
万方数据